Products
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Generics Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Biosimilar Education And Innovation Bills Head To Biden’s Desk
The Advancing Education on Biosimilars Act and the Ensuring Innovation Act will be looked at by the US President Joe Biden, after receiving the approval of both the Senate and the House of Representatives. The bills are aimed at lowering prescription drug costs and saving overall healthcare costs.
Aurobindo’s Latest Launches Include Truvada And Atripla Rivals
Aurobindo has announced the launch of generic versions of Truvada, Atripla, Minocin and Gleevec in the US. As its generics business grows in the US, Europe, Canada and the rest of the world markets, Aurobindo plans to establish itself in China. The Indian pharma company has also announced its plan to commission new facilities to serve the external market.
Teva Identifies ‘Problem Pattern’ Of Complex CRLs Ahead Of GDUFA III
Forecasting up to a dozen complex generic launches by Teva in the US in 2021, executive vice-president for North America commercial Brendan O’Grady said Teva was continuing to push for changes to boost approval rates ahead of GDUFA III next year.
Biosimilars Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Biosimilar Education And Innovation Bills Head To Biden’s Desk
The Advancing Education on Biosimilars Act and the Ensuring Innovation Act will be looked at by the US President Joe Biden, after receiving the approval of both the Senate and the House of Representatives. The bills are aimed at lowering prescription drug costs and saving overall healthcare costs.
Amgen Tells Sandoz On Enbrel: You Lost On The Facts
Amgen has hit back at Sandoz’ petition for a writ of certiorari against a US Court of Appeals for the Federal Circuit decision that leaves the biosimilar sponsor unable to market its Enbrel biosimilar more than three decades after the biologic was first launched.
PlantForm Strikes Deal For Brazilian Pembrolizumab
Canada’s PlantForm has struck a deal with Brazil’s Bio-Manguinhos/Fiocruz to develop a biosimilar pembrolizumab rival to Merck’s Keytruda for the Brazilian market and potentially beyond.
Value-Added Medicines Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Glenmark Finds Canadian Ryaltris Partner
Glenmark has struck the latest in a series of commercialization deals for its Ryaltris nasal spray in the form of a ten-year alliance with Bausch Health for the Canadian market.
Hyloris Sets Out Plans To Expand Its Pipeline
After partnering with companies like Purna Female Healthcare and AFT Pharmaceuticals, Belgian value-added medicines specialist Hyloris has announced plans to add three new products to its pipeline in the coming months with a goal of having 14 commercial products by 2024.
UK Set To Launch Drug Repurposing Project
Licensing new uses of existing medicines has several benefits over off-label use, such as offering assurances that the indication is evidence based and subject to an ongoing safety monitoring program, according to a new report.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.